Subcutaneous Implantable Defibrillator Market was valued at US$ 8.34 billion in 2022 and is predicted to reach US$ 12.44 billion by 2032, growing at a 4.3% CAGR.
| Report Attribute | Details |
|---|---|
| Market Value (2022) | US$ 8.34 Billion |
| Market Anticipated Value (2032) | US$ 12.44 Billion |
| Market Growth Rate (2022 to 2032) | 4.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the WHO, poor and middle-income countries account for more than three-quarters of all cardiovascular disease death.
Heart and blood vessel problems such as coronary heart disease, rheumatic heart disease, and others are examples of defibrillator diseases. According to the WHO, heart attacks and strokes account for over 80% of Defibrillator Disease deaths, with approximately one-third of these deaths occurring prematurely in adults under the age of 70. The growing prevalence of Defibrillator Diseases has resulted in a major increase in demand for subcutaneous implantable defibrillator devices.
S-ID Advantages Over Traditional Implantable Defibrillator (ID) to Drive Market Growth
The desire to reduce the danger of serious consequences associated with transvenous leads, such as bloodstream infections, as well as the requirement to remove or replace the leads in the heart, led to the creation of S-ID systems. S-ID is not the same as a traditional ID. In the S-ID systems, the wires, also known as leads, that connect the device to the heart are implanted beneath the skin, as opposed to the ID systems, where the leads are placed in the veins.
This process makes it easier to remove and replace the leads as needed. Such advantages of S-ID over conventional ID are expected to drive growth in the worldwide S-ID system market over the forecast period.
The global subcutaneous implantable defibrillator system market is predicted to expand rapidly in the coming years. One of the most crucial factors expected to fuel the expansion of this market in the next years is the increased prevalence of cardiovascular illnesses and other life-threatening arrhythmias. Furthermore, heart attacks and strokes were responsible for an estimated 43% of these deaths. These frightening statistics underscore the critical need for improved treatment options for cardiovascular disorders, which will drive a strong demand for subcutaneous implantable defibrillator systems in the next years.
Despite the rising market for subcutaneous implantable defibrillator systems, the high costs of deployment and maintenance act as a barrier to the expansion of the S-ID system industry. The inability of low- and middle-income countries to afford such an expensive surgery is expected to reduce demand for subcutaneous implantable defibrillator systems in the coming years.
Similar in functionality of the traditional Implantable Cardioverter Defibrillators (ICD), and the Transvenous Implantable Cardioverter Defibrillators (T-ICD), Subcutaneous Implantable Cardioverter Defibrillators (S-ICD’s), are used to treat patients with a history of life threatening Arrhythmias (ventricular tachycardia or fibrillation).
Unlike the conventional Implantable Defibrillators which are implanted intravascular, the Subcutaneous Implantable Defibrillators are inserted subcutaneously under the skin, and uses a subcutaneous electrode placed near the heart, rather than into the heart as in case of conventional Implantable Defibrillators.
A Subcutaneous Implantable Defibrillator consists of a small titanium case which contains battery, a subcutaneous electrode, and accessories such as insertion tool etc. If there is any abnormality in the patient’s heartbeat, the subcutaneous implantable defibrillator sends and electrical impulse to restore normalcy in the heart rhythm, followed by pacing therapy in form of post shock bradycardia, if needed. Implantable defibrillators are useful in saving patients’ lives with known history of ventricular tachycardia and arrhythmias.
The US-FDA recently approved the use of subcutaneous implantable defibrillators in 2012, following proven efficiency after clinical studies. According to a study published in the New England Journal of Medicine (2010), demonstrated a concept of the subcutaneous implantable defibrillators. Any person with a history of a congenital heart disease, heart attack, sudden cardiac arrest, or ventricular arrhythmia, may need a subcutaneous implantable defibrillator.
Principal Consultant
The global market for Subcutaneous Implantable Defibrillator is expected to be driven by the key advantages of the subcutaneous implantable defibrillators over the conventional Implantable defibrillators, such as the placement of electrode near the heart, rather than on the heart in case of conventional defibrillators which reduces risks, and longer shelf life, and ease of insertion and removal of the subcutaneous defibrillators.
Also Increasing incidences of cardiovascular diseases, increasing geriatric population around the world, changing lifestyle, increased smoking, rising prevalence of strokes, and increasing technological advancements in the medical devices industry are some of the factors responsible for the growth of the subcutaneous implantable defibrillators market during the forecast period of 2016-2024.
However patients with a history of symptomatic ventricular bradycardia, or patients with a heart failure for whom resynchronization is advised, cannot use subcutaneous implantable defibrillators as the device provides a post-shock pacing therapy whenever needed, and this can lead to complications in patients with bradycardia.
Another restraint for the growth of the subcutaneous implantable defibrillators market is that the clinical efficiency of the subcutaneous implantable defibrillators in general population is still not proved.
Ventricular Tachycardia in the indications segment is expected to dominate the global subcutaneous implantable defibrillators market during the forecast period, due to changing lifestyles leading to increasing cases of cardiac disorders, and increased smoking prevalence.
In the end users segment, hospitals is expected to dominate the global subcutaneous implantable defibrillators market, due to increasing cardiac surgeries, improving hospitals infrastructure and increased adoption of sophisticated and advanced technologies by hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Region wise, the global subcutaneous implantable defibrillator market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global market for implantable defibrillators, due to good reimbursement policies for surgical procedures, US-FDA approval and increased demand for subcutaneous implantable defibrillators.
Increasing incidences of cardiovascular diseases owing to changing lifestyle and increasing geriatric population in the Asia Pacific region is expected to boost the market growth in APEJ region.
Some of the key players in global Implantable Defibrillator market include Boston Scientific Corporation, LivaNova PLC Company, Imricor Medical Systems, Inc., MicroPort Scientific Corporation, Mayo Clinic US, Medtronic plc, MRI Interventions, Inc., and St. Jude Medical, Inc.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global Implantable Defibrillator market is classified on the basis of product type, procedure type, end user, and geography.
The market is likely to register a CAGR of 4.3% through 2032.
The market is currently valued at US$ 8.34 Bn in 2022.
The market is likely to grow to a valuation of US$ 12.44 Bn by 2032
North America is likely to be a leading market during the forecast period.
Explore Healthcare Insights
View Reports
Subcutaneous Implantable Defibrillator Market
